Lupin receives USFDA approval for Cephalexin Capsules. Mumbai, December 1, 2005: Lupin Ltd announced that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Cephalexin Capsules USP 250 mg and 500 mg. The US market for Cephalexin Capsules is estimated at USD 80 million.ts FY 2004-05 revenues were Rs.12 billion. 11 of Lupin's plant have been approved by the USFDA and two facilities have been approved by the UKMHRA For further information contact: Edith St-Hilaire LUPIN PHARMACEUTICALS, INC.